<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To assess the significance of phosphatidylinositol 3-kinase (PI3K) in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and toxicity of LY294002 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells with different metastatic abilities </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Sixty formalin-fixed and paraffin-embedded <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> specimens were investigated </plain></SENT>
<SENT sid="2" pm="."><plain>Adjacent <z:mpath ids='MPATH_458'>normal</z:mpath> colonic mucosa specimens from 10 of these cases were selected as controls </plain></SENT>
<SENT sid="3" pm="."><plain>PI3K protein was detected by immunohistochemistry and PIK3CA mutations were investigated by gene sequencing analysis </plain></SENT>
<SENT sid="4" pm="."><plain>A flow-cytometry-based <z:mpath ids='MPATH_3'>apoptosis</z:mpath> detection kit was used to determine PI3K inhibitor-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines SW480 and SW620 </plain></SENT>
<SENT sid="5" pm="."><plain>Expression of phosphorylated protein kinase B in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines was detected by Western blotting </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: There was a significant difference in the proportion of <z:e sem="disease" ids="C1402294" disease_type="Disease or Syndrome" abbrv="">primary lesions</z:e> (30%, 18/60) vs metastatic lesions (46.7%, 28/60) that were positive for PI3K (P &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>Mutations were detected in exon 9 (13.3%) and exon 20 (8.3%) </plain></SENT>
<SENT sid="8" pm="."><plain>Out of 60 cases, seven mutations were identified: two hotspot mutations, C.1633G&gt;A resulting in E545A, and C.3140A&gt;G resulting in H1047R; two novel missense mutations C.1624G&gt;A and C.3079G&gt;A; and three synonymous mutations (C.1641G&gt;A, C.1581C&gt;T and C.3027T&gt;A) </plain></SENT>
<SENT sid="9" pm="."><plain>Exposure of SW480 cells to PI3K inhibitor for 48 h resulted in a significant increase of apoptotic cells in a dose-dependent manner [3.2% apoptotic cells in 0 μmol/L, 4.3% in 5 μmol/L, 6.3% in 10 μmol/L (P &lt; 0.05), and 6.7% in 20 μmol/L (P &lt; 0.05)] </plain></SENT>
<SENT sid="10" pm="."><plain>Moreover, PI3K inhibitor induced a similar significant increase of apoptotic cells in the SW620 cell line for 48 h [3.3% apoptotic cells in 0 μmol/L, 13.3% in 5 μmol/L (P &lt; 0.01), 19.2% in 10 μmol/L (P &lt; 0.01), and 21.3% in 20 μmol/L (P &lt; 0.01)] </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: High PI3K expression is associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>PI3K inhibitor induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells and displayed strong cytotoxicity for highly metastatic cells </plain></SENT>
<SENT sid="13" pm="."><plain>PI3K inhibition may be an effective treatment for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>